Victory Capital Management Inc. Has $838,000 Holdings in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC)

Key Points

• Victory Capital Management Inc. increased its stake in Oric Pharmaceuticals by 54.1%, owning 150,260 shares valued at approximately $838,000 after purchasing an additional 52,760 shares in the 1st quarter.
• Oric Pharmaceuticals' stock has seen significant interest from analysts, with nine investment analysts rating it as a "Buy" and an average price target of $18.57.
• Despite the positive analyst sentiment, Oric Pharmaceuticals' shares opened at $9.97, reflecting a 6.9% decline, while the company reported a quarterly loss of $0.42 per share, exceeding estimates.

Victory Capital Management Inc. grew its holdings in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 54.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,260 shares of the company's stock after purchasing an additional 52,760 shares during the quarter. Victory Capital Management Inc. owned approximately 0.21% of Oric Pharmaceuticals worth $838,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. New York State Common Retirement Fund lifted its stake in shares of Oric Pharmaceuticals by 137.1% during the first quarter. New York State Common Retirement Fund now owns 38,486 shares of the company's stock valued at $215,000 after buying an additional 22,257 shares during the period. Arizona State Retirement System purchased a new stake in Oric Pharmaceuticals during the 1st quarter worth $56,000. Wellington Management Group LLP increased its stake in Oric Pharmaceuticals by 6.9% during the 4th quarter. Wellington Management Group LLP now owns 186,430 shares of the company's stock worth $1,504,000 after buying an additional 12,042 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Oric Pharmaceuticals by 54.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,579 shares of the company's stock worth $287,000 after buying an additional 12,545 shares during the period. Finally, Two Sigma Advisers LP grew its holdings in Oric Pharmaceuticals by 14.3% during the 4th quarter. Two Sigma Advisers LP now owns 66,500 shares of the company's stock worth $537,000 after acquiring an additional 8,300 shares in the last quarter. 95.05% of the stock is currently owned by institutional investors and hedge funds.

Oric Pharmaceuticals Stock Up 1.5%

Oric Pharmaceuticals stock traded up $0.15 during trading hours on Friday, hitting $10.12. 942,341 shares of the company traded hands, compared to its average volume of 1,164,141. The firm's 50-day simple moving average is $9.94 and its two-hundred day simple moving average is $8.15. The firm has a market cap of $862.43 million, a P/E ratio of -5.41 and a beta of 1.69. Oric Pharmaceuticals, Inc. has a 1-year low of $3.90 and a 1-year high of $14.67.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.09. On average, equities research analysts predict that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Angie You bought 26,597 shares of the business's stock in a transaction on Friday, June 20th. The stock was purchased at an average cost of $9.39 per share, for a total transaction of $249,745.83. Following the completion of the transaction, the director directly owned 26,597 shares of the company's stock, valued at approximately $249,745.83. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Dominic Piscitelli sold 32,466 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total value of $340,893.00. Following the completion of the sale, the chief financial officer owned 68,317 shares of the company's stock, valued at $717,328.50. This trade represents a 32.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,000 shares of company stock valued at $416,289 over the last 90 days. 6.82% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on ORIC. HC Wainwright reaffirmed a "buy" rating and issued a $21.00 price target on shares of Oric Pharmaceuticals in a report on Monday, May 5th. Oppenheimer cut their target price on Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Wedbush reaffirmed an "outperform" rating and issued a $20.00 price objective on shares of Oric Pharmaceuticals in a report on Monday, June 23rd. LADENBURG THALM/SH SH assumed coverage on shares of Oric Pharmaceuticals in a research note on Tuesday, July 8th. They set a "buy" rating and a $15.00 target price for the company. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $18.57.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.